SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 5, 2006--Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on advancing cancer care, today reviewed 2005 progress and announced its corporate objectives for 2006. Key 2005 achievements for Hana include: Q1 05: Zensana(TM) pilot pharmacokinetic study demonstrated pharmacokinetic profile comparable to oral Zofran(R), with multidose convenience and faster drug delivery.
